Cytokinetics (CYTK) Stock Price, News & Analysis

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

15 equities research analysts have issued twelve-month price targets for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $108.00. On average, they predict the company's share price to reach $79.33 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK stock has decreased by 19.8% and is now trading at $67.00.
View the best growth stocks for 2024 here.

Cytokinetics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 13,230,000 shares, a decrease of 10.6% from the March 15th total of 14,800,000 shares. Based on an average daily volume of 3,170,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 13.3% of the company's stock are short sold.
View Cytokinetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYTK earnings forecast.

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to analyst estimates of $7.62 million. The business's revenue for the quarter was down 10.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.45) EPS.

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Harbor Health Care ETF (MEDI), BNY Mellon Innovators ETF (BKIV), American Century Mid Cap Growth Impact (MID) and Principal Healthcare Innovators ETF (BTEC).

Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Mirador Capital Partners LP (0.03%), State of Michigan Retirement System (0.02%), Los Angeles Capital Management LLC (0.02%), Wealth Enhancement Advisory Services LLC (0.01%), Cannon Global Investment Management LLC (0.01%) and First Bank & Trust (0.01%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.